Introduction
============

Human papillomaviruses (HPV), particularly those of the beta genus (beta-PV), have long been proposed as cofactors with ultraviolet radiation in the pathogenesis of cutaneous squamous cell carcinoma (cSCC), especially those associated with the rare genodermatosis, epidermodysplasia verruciformis and with immune suppression ([@B87]; [@B50]; [@B64]; [@B45]). Over the past decade, 13 human polyomaviruses (HPyV) have been identified and classified ([@B13]) and those with affinity for the skin include HPyV6, HPyV7, HPyV9, the trichodysplasia spinulosa-associated polyomavirus (TSPyV), the Merkel cell polyomavirus (MCPyV) ([@B23]; [@B30]; [@B81], [@B79]; [@B58]) and the Lyon IARC polyomavirus (LIPyV) ([@B38]). MCPyV was the first to be associated with malignancy -- the aggressive cutaneous neuroendocrine cancer Merkel cell carcinoma ([@B31]; [@B72]) -- and has also been investigated in the context of cSCC ([@B27]; [@B70]). More recently, the clinical and histologic features of cSCCs and other squamoproliferative lesions that complicate treatment for metastatic melanoma with oral small molecule *BRAF* inhibitors (BRAFi) have raised the possibility of significant viral involvement in their pathogenesis ([@B8]). Both HPV and HPyV have been investigated, but studies have to date provided conflicting evidence for their role. With the prospect of future widespread adjuvant use of these drugs ([@B55]; [@B57]), a more detailed understanding of the pathogenesis of BRAFi-induced cSCC (BRAFi-SCC) remains important.

Oncogenic mutations in the oncoprotein *BRAF*, which encodes the growth signal transduction serine/threonine protein kinase B-Raf, are found in approximately 50% of melanomas and result in constitutive activation of the RAS/mitogen-activated protein kinase (MAPK) pathway. The most common BRAF mutation results in a substitution of a valine (V) residue to glutamic acid (E) at amino acid position 600 (V600E) ([@B56]). This locks the kinase into the active conformation and results in melanocyte hyperproliferation. BRAF inhibitors have been developed that exploit this mutation and competitively bind to the active conformation of the kinase ([@B99]; [@B65]) Vemurafenib and dabrafenib are two such selective small molecule inhibitors of oncogenic *BRAF* and are associated with high response rates and improved progression-free survival and overall survival compared with chemotherapy in patients with BRAFV600 mutated melanoma ([@B17]). However, responses are generally temporary, with a median time to relapse of approximately 6 months. Vemurafenib entered routine clinical use in 2011/2012 and has been associated with various cutaneous adverse effects. These include rashes, photosensitivity, hyperkeratosis and development of *de novo* squamoproliferative lesions in 16--26.7% of patients, ranging from benign VW and squamous papillomas/verrucous keratoses (VK) to keratoacanthomas (KA) and cSCC ([@B33]; [@B73]; [@B1]; [@B6]; [@B17]). The median time to presentation for BRAFi-SCC is 8--12 weeks and it is argued that this rapid timeframe points to pre-existing mutations being given a selective advantage due to BRAFi treatment, rather than mutations arising *de novo* due to therapy. Consistent with this mechanism, there is evidence for paradoxical hyperactivation of the MAPK pathway in cells with wild-type BRAF but mutated RAS through allosteric and catalytic mechanisms that relieve the auto-inhibition of wild-type RAF kinase ([@B47]; [@B48]; [@B61]). Indeed, many of these BRAFi features overlap with the cutaneous manifestations of RASopathies -- genetic diseases such as cardiofaciocutaneous and Costello syndromes characterized by activating germ line mutations in RAS ([@B66]; [@B71]). Also consistent with this, 18--60% of BRAFi-cSCC have somatic mutations in HRAS or KRAS, which is significantly higher than in sporadic cSCC ([@B59]; [@B76]; [@B74]). Nevertheless, many BRAFi-cSCC are RAS wild type, and RAS mutations have been also been detected in benign epithelial skin lesions ([@B74]; [@B46]), suggesting that accelerated oncogenesis of RAS-mutated cells is not the only aetiologic mechanism and that additional cofactors may be involved. Attention has focused on infectious agents, particularly oncogenic viruses. HPV has been the main candidate given its previous proposed role in EV and immune suppression-associated cSCCs, coupled with evidence in BRAFi-cSCC of clinical and histological patterns of viral wart-like features and overexpression of p16 ([@B8]). Human polyomaviruses, particularly MCPyV, have also been investigated but, to date, the available evidence for both HPV and HPyV remains inconclusive ([@B2]; [@B18]; [@B8]; [@B37]; [@B28], [@B29]; [@B52]; [@B36]; [@B49]; [@B69]; [@B20]; [@B24]; [@B83],[@B84]).

Single agent BRAFi therapy has generally been replaced by combination BRAFi and MEK inhibition (MEKi): phase III studies demonstrated improved clinical outcomes and significantly delayed resistance compared with BRAFi alone and BRAFi-MEKi combination therapy (vemurafenib/cobimetanib and dabrafenib/trametinib) is now the standard of care for BRAF mutated metastatic melanoma ([@B32]; [@B54]). Combination therapy also results in decreased incidence of BRAFi-SCC to around 4%, which may be due to the fact that MEKi bypasses the point of paradoxical RAF activation ([@B26]). Although rates of BRAFi-SCC are consequently reduced with combination therapy, these drugs are now being introduced as adjuvant treatment in high-risk, non-metastatic primary melanoma (stages IIC--IIIA--IIIB--IIIC). In the recent BRIM-8 study of adjuvant vemurafenib in BRAF-mutated melanoma, 16% of patients treated with adjuvant vemurafenib had BRAFi-cSCC or KA ([@B57]). This incidence is considerably lower with BRAFi-MEKi combination adjuvant therapy ([@B55]), but with approval for adjuvant treatment comes the prospect of a huge increase in the numbers of patients receiving these agents in the near future. The need to better understand the pathogenesis of their associated cSCC therefore remains important.

In this study we have examined HPV and HPyV status in a series of benign and malignant BRAFi-associated skin lesions and correlated these data with key clinical, histologic and genetic parameters in order to further investigate the contribution of these viruses to the pathogenesis of BRAFi-induced skin tumors.

Materials and Methods {#s1}
=====================

Patients and Samples
--------------------

Patients were recruited from the melanoma clinic at Barts Health NHS Trust. Punch biopsies were taken after surgical excision of lesions or from bisected shave biopsies. They were immediately snap-frozen in liquid nitrogen and stored at −80°C. The remainder of the tissue was sent for formalin fixation and histologic diagnosis. In order to enrich for tumor cell populations, fresh-frozen samples were laser-capture microdissected using the Zeiss Palm Microbeam microscope (Zeiss, Cambridge, United Kingdom). Depending on sample size and purity, as estimated from a reference hematoxylin and eosin slide, between 30 and 60 sections of 8 mm thickness were cut onto 1.0 mm PEN membrane slides (Zeiss), stained in 0.05% acid fuchsin (Acros Organics, Morris Plains, NJ, United States) in distilled water and 0.05% toluidine blue O (Acros Organics, Morris Plains, NJ, United States) in 70% ethanol, and microdissected, with tumor cells collected into 180 μl ATL buffer (Qiagen, Crawley, United Kingdom). All sections were cut using a fresh microtome to prevent cross-contamination. DNA extraction was performed using the QIAamp DNA micro kit (Qiagen, Crawley, United Kingdom) according to the manufacturer's instructions. To provide a source of germline DNA, paired venous blood samples were obtained concomitantly with lesional tissue and stored at −80°C before DNA extraction using the QIAamp DNA blood mini kit (Qiagen, Crawley, United Kingdom). The quality of the extracted DNA was assessed by β-globin reference gene PCR.

Histopathology
--------------

Histology sections were prepared from formalin-fixed paraffin-embedded tissue and stained with hematoxylin and eosin under standard conditions. All diagnoses were confirmed after review by an experienced dermatopathologist (HR). Samples were scored as having features consistent with viral infection if koilocytosis was observed in conjunction with at least three of the following five features: acanthosis, hypergranulosis, parakeratosis, hyperkeratosis, and typical papillomatous architecture. Consensus scoring of viral features was reached with two additional observers (KP, CH).

HPV Detection and Genotyping
----------------------------

Beta, gamma, alpha, mu, nu, and novel HPV types were detected using a comprehensive panel of HPV detection and typing methodologies. The presence of beta-HPV was investigated using RHA kit skin (beta) HPV detection system ([@B22]) according to the manufacturer's instructions (Diassay, Rijswijk, The Netherlands). In addition, the RHA kit HPV SPF10-LiPA25 (Labo Bio-medical products BV, Rijswijk, The Netherlands) was used to detect the presence of 25 high- and low-risk mucosotropic alpha-HPVs, according to the manufacturer's instructions. Degenerate nested PCR protocols were used to investigate the presence of cutaneous alpha-HPV and mu and nu genera ([@B43]) and the gamma genus ([@B34]; [@B3]).

Polyomavirus Detection and Genotyping
-------------------------------------

In lesional samples for which sufficient DNA was available, quantitative PCR was performed as previously described ([@B82], [@B80]), to determine the presence and load of HPyV9, MCPyV, and TSPyV. For HPyV6 and HPyV7 quantitative PCR the following primers and probes located in VP1 were used: 5′-GTAGGGTATGCTGGTAAC-3′ (HPyV6 sense), 5′-CAGGAATTGTCTAAACATCATATC-3′ (HPyV6 antisense), 5′-CTCTCCTCTGTCTGAAGTGAACTC-TAA-3′ (HPyV6 probe), 5′-GTGCTGATATGGTTGGAA-3′ (HPyV7 sense), 5′-TCTGCAGTGGACTCTAAA-3′ (HPyV7 antisense), 5′-AGCCTGTACTGTTCTCTGGTTACT-3′ (HPyV7 probe). Input cell equivalents were determined by normalization to beta-globin.

All DNA extractions and PCRs for both HPV and HPyV were performed using standard operating procedures designed to reduce the possibility of contamination ([@B43]). DNA extraction, water and buffer PCR controls were used to exclude contamination and these were consistently negative.

Immunohistochemistry
--------------------

Immunofluorescence analysis was carried out using polyclonal antibodies raised against the E4 proteins of HPV 5, 8, and 23 (beta-PV types), or the E4 protein of HPV2 and 57 (alpha-PV types) using the protocols previously described ([@B40]). In the double staining experiments, a monoclonal antibody (8H3) prepared against the HPV 8 E4 protein was used in place of the beta-PV E4 polyclonal antibodies. Polyclonal and monoclonal antibodies were prepared against GST-E4 fusion proteins ([@B25]; [@B7]). Techniques for the overlay of fluorescence staining patterns onto the hematoxylin and eosin sections have been described previously ([@B41]). All tissue sections were formalin fixed prior to staining. Sections were counterstained with DAPI to visualize cell nuclei.

SNP Array Analysis of Gross Chromosomal Aberrations
---------------------------------------------------

Cutaneous squamous cell carcinoma and paired venous blood DNA samples were subjected to the GeneChip Genome-Wide Human SNP Array 6.0 assay (Affymetrix Inc., Santa Clara, CA, United States) according to the manufacturer's protocol. Processing was performed as previously described ([@B77]) using the Genome Oriented Laboratory File (GOLF) system for the analysis and display of single nucleotide polymorphism (SNP) signal data. Copy number profiles of vemurafenib-associated cSCC were compared with those observed in a previous study of sporadic cSCC ([@B63]).

Genetic Mutational Analysis
---------------------------

Targeted genetic analysis of all samples was undertaken using 454 pyrosequencing performed using the GS Junior system (Roche/454 Life Sciences, Branford, CT, United States) and Fluidigm (Fluidigm Corporation, San Francisco, CA, United States) PCR amplicon libraries as template. In addition to *H, K*, and *NRAS*, we also analyzed the genes *NOTCH1, NOTCH2, TP53, CDKN2A, CARD11, CREBBP, TGFBR1*, and *2*, all of which our previous research has implicated in the pathogenesis of cSCC ([@B12]; [@B74]; [@B14]; [@B89], [@B90]). Primers were designed and validated by Fluidigm (Fluidigm Corporation, San Francisco, CA, United States) as per recommended guidelines for Roche Titanium sequencing (Roche, Mannheim, Germany). Variant detection required a minimum of four supporting reads and a minimum variant allele frequency threshold of 0.1. Detailed genetic analysis of these samples has previously been reported ([@B74]; [@B14]).

Ethical Approval
----------------

This study was carried out in accordance with the recommendations of East London and City Health Authority local ethics committee. The protocol was approved by the East London and City Health Authority local ethics committee. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

Results
=======

Patients
--------

A total of seven patients with 45 skin lesions were recruited (**Figures [1](#F3){ref-type="fig"}**, **[2](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). They included 4 men (mean age 61.25 years, range 35--87 years) and 3 women (mean age 56.3 years, range 33--82 years). All patients had metastatic melanoma with V600E BRAF mutations. All were treated in 2012--2013 with single agent vemurafenib. For all patients, samples were collected at first presentation with skin lesions after starting vemurafenib. The mean time to either disease progression (*n* = 3 patients) or death from melanoma whilst receiving vemurafenib (*n* = 4 patients) was 7.7 months (range 3--17 months).

![Viral-wart like lesions developing after BRAFi exposure. **(A)** Lesion V10, viral wart on chin of patient 2; **(B)** Viral warts on the neck and chin of patient 1; **(C)** Viral wart on the eyelid of patient 5; **(D)** Lesion V22, post-auricular viral wart in patient 3.](fmicb-09-01806-g001){#F1}

![Cutaneous squamous cell carcinomas developing after BRAFi exposure. **(A)** Well-differentiated SCC on the ear of patient 1; **(B)** Lesion V4, well-differentiated SCC on the arm of patient 1.](fmicb-09-01806-g002){#F2}

###### 

Clinical, histologic, viral, and genetic features of the seven patients and 45 lesions analyzed.

  Pt      Sex/age (years)   Lesion code   Weeks on BRAFi^1^ (weeks)   Body site         SE/NSE^2^   Diagnosis^3^   Viral features^4^   Mutations^5^                                                 Beta-PV^6^                             Alpha-PV   Gamma-PV   IHC^7^     HPyV6^8^        HPyV7^8^       HPyV9^8^     TSPyV^8^   MCPyV^8^
  ------- ----------------- ------------- --------------------------- ----------------- ----------- -------------- ------------------- ------------------------------------------------------------ -------------------------------------- ---------- ---------- ---------- --------------- -------------- ------------ ---------- --------------
  **1**   M/67              V1            9                           Scalp             SE          VW             Y                   NOTCH1, CREBBP                                               8, 9, 36, 38, 111                      28                    ND         7.5 × 10^−6^    3.6 × 10^−2^   Neg          Neg        1.7 × 10^−2^
                            V2            9                           Suprapubic        NSE         V K            Y                   NOTCH1, HRAS, CARD11                                         8, 24, 36, 92, 111                                           ND         ND              ND             ND           ND         ND
                            V3            9                           Post-auricular    SE          VW             Y                   TGFBR2, CDKN2a, CARD11, NOTCH2, CREBBP                       8, 36                                                        ND         ND              ND             ND           ND         ND
                            V4            9                           Arm               SE          SCC            Y                   TGFBR1, NOTCH1, HRAS                                         8, 12, 24, 36, 111, FA51                                     ND         Neg             1.7 × 10^−4^   Neg          Neg        4.6 × 10^−2^
                            V5            9                           Inner Thigh       NSE         VW             Y                   NOTCH1, NOTCH2, HRAS, CREBBP                                 8, 12, 36, 111                                               ND         2.9 × 10^−4^    Neg            Neg          Neg        2.8 × 10^−2^
                            V6            9                           Lower Back        NSE         SCC            Y                   TP53, HRAS                                                   12, 36, 92                                                   ND         5.12 × 10^−5^   1.3 × 10^−1^   Neg          Neg        3.9 × 10^−3^
                            V7            9                           Shoulder          NSE         SCC            Y                   NOTCH1, TP53, TGFBR1, CREBBP                                 15, 24, 36, 76, 92, 107, FA84                                Neg        Neg             3.9 × 10^−5^   Neg          Neg        1.8 × 10^−2^
                            V8            9                           Posterior neck    SE          VK             Y                   NOTCH1, CARD11, TGFBR1                                       8, 24, 36, 93                                                Neg        4.6 × 10^−5^    4.8 × 10^−4^   Neg          Neg        2.3 × 10^−1^
                            V9            9                           Cheek             SE          VW             Y                   HRAS, TP53^∗^, NOTCH1,^∗^ NOTCH2^∗^                          8, 12, 24, 36, 76, 92 93               28                    ND         ND              ND             ND           ND         ND
                            V11           13                          Scalp             SE          VW             Y                   NOTCH1, TGFBR2, CARD11, CREBBP                               8,23, 36, 92, 93                                             Neg        Neg             2.2 × 10^−4^   Neg          Neg        1 × 10^−1^
                            V12           13                          Abdomen           NSE         N-NSE          N                   NOTCH1                                                       5, 92                                                        ND         ND              ND             ND           ND         ND
                            V13           13                          Lower back        NSE         SCC            Y                   Nil                                                          8, 24, 92, 107, 111, FA14                                    Neg        3.9 × 10^−5^    2.4 × 10^−4^   Neg          Neg        5.9 × 10^−3^
                            V14           13                          Popliteal Fossa   NSE         VW             Y                   NOTCH1, CREBBP                                               12, 24, 36                                                   ND         Neg             1.3 × 10^−2^   Neg          Neg        1.7 × 10^−3^
                            V15           13                          Post-auricular    SE          VW             Y                   CARD11                                                       93                                                           ND         Neg             1.6 × 10^−3^   Neg          Neg        5.6 × 10^−2^
                            V16           13                          Abdomen           NSE         VW             Y                   TP53, HRAS                                                   8, 36, 92, 93                                                ND         Neg             6, × 10^−4^    Neg          Neg        9.9 × 10^−3^
                            V17           13                          Abdomen           NSE         VW             Y                   NOTCH1, CDKN2a                                               8, 36, 92, 113                                               ND         Neg             1.4 × 10^−1^   Neg          Neg        6.2 × 10^−4^
                            V18           14                          Chest             NSE         VW             Y                   NOTCH1, HRAS, KRAS                                           8^∗∗^, 12, 24, 76, 92^∗∗^, 111                               Neg        1.12 × 10^−5^   5, × 10^−5^    Neg          Neg        5.8 × 10^−3^
                            V19           14                          Groin             NSE         SCC            Y                   HRAS, NOTCH1                                                 8, 12, 24, 36, 92                                            Neg        3.93 × 10^−6^   1.4 × 10^−4^   Neg          Neg        3.6 × 10^−3^
                            V20           14                          Chest             SE          SCC            Y                   Nil                                                          8, 12, 24, 92^∗∗^, 93                                        Neg        1.29 × 10^−5^   2.4 × 10^−4^   Neg          Neg        1.2 × 10^−2^
                            V25           18                          Arm               SE          N-P V27        N                   NOTCH1                                                       Neg                                                          ND         ND              ND             ND           ND         ND
                            V26           18                          Abdomen           NSE         VW             Y                   CARD11, NOTCH1, HRAS, CREBBP                                 8, 92                                                        Neg        Neg             5.9 × 10^−5^   Neg          Neg        5.3 × 10^−3^
                            V27           18                          Upper arm         SE          SCC            Y                   HRAS, CARD11, CREBBP, NOTCH1 NOTCH2^∗^ KRAS^∗^ TP53^∗^       Novel                                                        Neg        Neg             Neg            Neg          Neg        Neg
                            V28           18                          Lower abdomen     NSE         SCC            Y                   NOTCH2, NOTCH1^∗^                                            Neg                                                          Neg        ND              ND             ND           ND         ND
                            V31           34                          Cheek             SE          VK             N                   Nil                                                          Novel                                                        ND         3.66 × 10^−6^   2.4 × 10^−4^   Neg          Neg        7.6 × 10^−3^
                            V32           34                          Upper Arm         SE          VW             Y                   NOTCH1, NOTCH2, HRAS, CREBBP, TP53^∗^                        24^∗∗^, 36, 92, 93                                           ND         ND              ND             ND           ND         ND
  **2**   M/35              V10           13                          Chin              SE          VW             Y                   Nil                                                          8, 12, 80^∗∗^, 76                      57^∗∗^                57, beta   ND              ND             ND           ND         ND
                            V29           28                          Scapula           NSE         VW             Y                   NOTCH2, CREBBP                                               12^∗∗^, 8, 20, 23, 36,76, 80, 92, 96   57                    ND         ND              D              ND           ND         ND
  **3**   M/56              V21           8                           Neck              SE          VK             N                   HRAS, CARD11, NOTCH1 ^∗^ NOTCH2^∗^                           22, 115, 150                                                 ND         3.73 × 10^−5^   6.4 × 10^−5^   Neg          Neg        Neg
                            V22           14                          Post-auricular    SE          VW             Y                   TGFBR1, HRAS NOTCH2^∗^                                       22, 107                                                      ND         ND              ND             ND           ND         ND
                            V23           14                          Upper arm         SE          SCC            Y                   CREBBP, CARD11, TGFBR1, NOTCH2^∗^                            2, 14D, 22, 38, 107, 115                                     Neg        Neg             Neg            Neg          Neg        1.3 × 10^−4^
                            V24           14                          Upper Arm         SE          N-P to V23     N                   NOTCH1                                                       Novel                                                        ND         ND              ND             ND           ND         ND
  **4**   F/33              V30           16                          Abdomen           NSE         SCC            N                   TP53, HRAS, NOTCH1^∗^ NOTCH2^∗^                              Neg                                               FA49       ND         Neg             Neg            Neg          Neg        Neg
  **5**   M/87              V33           6                           Ear               SE          VW             Y                   NOTCH1, TP53                                                 9                                                            ND         Neg             Neg            Neg          Neg        Neg
                            V34           6                           Chin              SE          AK             Y                   Nil                                                          9, 38                                                        ND         Neg             1.5 × 10^−5^   Neg          Neg        Neg
  **6**   F/82              V35           12                          Neck              SE          SCC            Y                   TGFBR1, TGFBR2, NOTCH1, TP53, KRAS, NOTCH2, CARD11, CREBBP   Neg                                                          ND         Neg             Neg            Neg          Neg        Neg
                            V36           12                          Neck              SE          N-P V35        N                   Nil                                                          Neg                                                          ND         ND              ND             ND           ND         ND
                            V37           12                          Neck              SE          N -SE          N                   NOTCH1, CARD11                                               Neg                                                          ND         ND              ND             ND           ND         ND
                            V38           12                          Shoulder          NSE         VW             Y                   TGFBR1, TGFBR2, TP53, KRAS, NRAS, CARD11, CREBBP             Neg                                                          ND         ND              ND             ND           ND         ND
                            V39           12                          Lower Leg         SE          SP             Y                   TGFBR1, NOTCH1, NOTCH2,, TP53, CREBBP                        Neg                                                          ND         Neg             Neg            Neg          Neg        1.5 × 10^−3^
                            V40           12                          Arm               SE          SCC            Y                   TGFBR2, CREBBP                                               Neg                                                          ND         Neg             Neg            4 × 10^−4^   Neg        2.9 × 10^−3^
  **7**   F/54              V41           11.5                        Neck              SE          N-SE           N                   NOTCH2, CREBBP                                               Novel                                                        ND         ND              ND             ND           ND         ND
                            V42           11.5                        Back              NSE         VW             Y                   TP53                                                         80                                                           ND         Neg             Neg            Neg          Neg        Neg
                            V43           11.5                        Back              NSE         M                                  NOTCH1, NOTCH2, NRAS, CARD11, CREBBP                         80                                                           ND         Neg             Neg            Neg          Neg        9 × 10^−4^
                            V44           11.5                        Back              NSE         VW             Y                   CARD11                                                       80^∗∗^                                                       ND         Neg             Neg            Neg          Neg        Neg
                            V45           11.5                        Back              NSE         AK             Y                   NOTCH1, TP53                                                 80                                                           ND         Neg             Neg            Neg          Neg        1.4 × 10^−4^

1

Weeks on BRAFi: number of weeks on vemurafenib at the time lesion was removed.

2

SE/NSE: Sun exposed or non-sun exposed body site.

3

Diagnosis: SCC -- well differentiated SCC; V, viral wart; VK, verrucous keratosis; AK, actinic keratosis; N-P, normal skin perilesional to; N-SE, normal skin sun exposed; N-NSE -- normal skin non sun exposed; M, benign melanocytic; SP, squamoproliferative lesion with viral features and dysplasia but no clear evidence of invasion.

4

Viral features: Y, yes; N, no: yes if koilocytosis was observed in conjunction with at least 3 of the following 5 features: acanthosis, hypergranulosis, parakeratosis, hyperkeratosis and typical papillomatous architecture.

5

Mutations: these have previously been published (South, 2014; Cammareri, 2016).

∗

indicates lesion bisected and results represent total mutations found across both portions.

6

Beta-PV: beta HPV types. Beta-PV types associated with strong bands on the RH assay are recorded as

∗∗

; neg, negative.

7

IHC; immunohistochemistry -- performed on 12 selected lesions.

8

HPyV6, -7, -9, TSPyV and MCPyV: neg, negative; N/D, not done; values recorded are viral copies per cell.

Samples (**Table [1](#T1){ref-type="table"}**)
----------------------------------------------

Samples consisted of 12 SCC, 19 VW, 2 actinic keratoses (AK), one melanocytic lesion and 6 non-lesional skin samples (3 normal skin and 3 normal skin perilesional to cSCC), 4 verrucous keratoses (VK -- squamous papillomas, some with viral features but without evidence of dysplasia) and one squamoproliferative (SP) lesion with viral features and dysplasia but no clear invasion (SP). Lesions were from both chronically sun-exposed (SE) and non-chronically sun-exposed (NSE) sites. SE sites included head and neck, arms, and lower legs in females. NSE included all other sun-protected sites. Lesions from SE sites included 6/12 (50%) cSCCs, 5/5 VKs, 9/19 (47%) VWs, and 1/2 AKs. The normal skin samples comprised 2 SE, one NSE and 3 perilesional to SCCs on SE sites.

The mean time to development of biopsy-proven lesions after initiation of vemurafenib was 8.75 weeks for AK (range 6--11.25), 9.7 weeks for VK/SP (range 8--12), 9.9 weeks for VW (range 6--13), and 11.25 weeks for cSCC (range 8--16 weeks). For 2 patients, additional samples were collected at more than one further time point: for patient 1, samples were collected at 9, 13, 14, 18, and 34 weeks; for patient 2, at 9 and 28 weeks.

Histopathology
--------------

Significant histological features of viral infection (i.e., koilocytosis and at least three of acanthosis, hypergranulosis, parakeratosis, hyperkeratosis or typical papillomatous architecture) were seen in all VW and AKs, 10/12 (83%) SCC, but no normal skin or VK samples (**Figure [3](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**).

![Histology of lesion V4: Micro invasion in an SCC from patient 1 with features of viral infection in overlying and adjacent epidermis.](fmicb-09-01806-g003){#F3}

Detection of Human Papillomavirus and Human Polyomaviruses
----------------------------------------------------------

### Human Papillomavirus Detection

Human papillomavirus DNA was detected in 18/19 (95%) VW, 9/12 (75%) SCC, 2/2 AK, 4/5 (80%) VK/SPs, and 3/6 (50%) normal skin samples (**Table [1](#T1){ref-type="table"}**). HPV positivity was significantly higher in VW compared to normal skin (Fisher's exact test: *p* = 0.0312,) but not in cSCC (Fisher's exact test: *p* = 0.344). Multiple HPV types were detected in 28/37 (76%) of HPV positive samples, with a median number of 4 in VW and 3 in SCC compared with 0.5 in normal skin (two-sided Mann--Whitney *U*-test: *p* = 0.007 for VW and 0.13 for SCC).

Cutaneous beta-PV were detected in all HPV positive lesions, with HPV-8, 12, 24, 36, and 92 the most frequent types. Alpha genus HPV types (alpha-PV) were found VW only (4/19, 21%) and were mucocutaneous alpha-PVs (HPV28 and HPV57), but not low or high-risk mucosal alpha-PVs. One cSCC contained a gamma HPV type. Although the RHA detection methodology used for beta and alpha-PV detection is not strictly quantitative, band intensity provides a surrogate read-out for predicted viral load. Analysis of these data suggested that the majority of HPV positive samples were likely to be associated with low viral load: the bands identified were faint or very faint in all cases, with the exception of samples V10, V18, V20, V29, V44 in which strongly positive bands were obtained for HPV types 57, 12, and 80. Four of these five lesions were VWs.

In all patients except one, multiple lesions were analyzed. Clear patterns of HPV carriage for each individual emerged. For example, beta-PVs 8, 12, 24, 36, 92, 93, and 111 were detected in patient 1 across both benign and malignant lesions at different body sites; this patient's normal, non-sun exposed skin sample also harbored HPV92 in addition to HPV5. Patient 2 had a spectrum of HPV types (HPV8, 12, 76, 80, and 57) that were concordant in VW at two separate body sites. Three other patients with more than one HPV positive lesion also had similar individual repertoires of HPV types across at least 2 lesions (patient 3, HPVs 22, 107; patient 4, HPV9; patient 7, HPV80). In the case of patient 6, all samples were negative, including two normal skin samples.

Only a minority of the 36 lesions with significant viral features on histological assessment had high levels of HPV DNA indicative of active infection. However, the 9 samples with no histological evidence of viral change (one cSCC, 2 VKs and 6 normal/perilesional skin samples) had significantly fewer HPV types detected compared to lesions with histological evidence of viral change (2-tailed Mann--Whitney *U*-test: *p* = 0.0114).

Immunohistochemistry was used to further investigate HPV DNA detection in a subset of 12 lesions. Although all had been HPV positive with multiple types detected, HPV protein expression was detected in only a single sample, a viral wart that had been strongly positive for both HPV57 and HPV80: both HPV57 and beta-PV were detected, but were expressed in spatially distinct cells within the lesion (**Figure [4](#F4){ref-type="fig"}**).

![Human papillomavirus immunohistochemistry. **(A,D)** Hematoxylin and eosin stained sections of 2 different areas of lesion V10 (strongly PCR positive for beta-PV types 8, 12, 76, 80, and alpha-PV 57); **(B,E)** double staining immunofluorescence with antibodies to the E4 protein of HPV8 (green) and HPV2/57 (red); **(C,F)** H&E stained sections overlaid with the images from immunofluorescence microscopy to identify cells with productive HPV infection.](fmicb-09-01806-g004){#F4}

### Human Polyomavirus Detection

Thirty lesional samples from 5 individuals were tested for the presence of HPyV (VW, *n* = 12; SCC, *n* = 11; VK/SP, *n* = 4; AK, *n* = 2; melanocytic, *n* = 1). Normal skin was not examined. The majority of samples were positive for at least one HPyV, albeit at low levels and independent of the presence or absence of significant histological viral features (**Table [1](#T1){ref-type="table"}**). Individual HPyV positivity ranged from 0% positivity for TSPyV; 3.3% for HPyV9 (SCC, *n* = 1); 33% for HPyV6 (VW, *n* = 3, 25%; SCC, *n* = 4, 36%; VK, *n* = 3, 36%); 60% for HPyV7 (VW, *n* = 8, 67%; SCC, *n* = 6, 54%; VK, *n* = 3, 25%; AK, *n* = 1, 50%) to 73% positivity for MCPyV (VW, *n* = 9, 75%; SCC, *n* = 8, 73%; VK, *n* = 3, 75%; AK, *n* = 1, 50%; melanocytic, *n* = 1, 100%). For all viruses, the difference in positivity between BRAFi-cSCC and VW was not significant (Fisher's exact test: *p* = 1 for HPyV9, HPyV6, MCPyV; *p* = 0.68 for HPyV7). Viral loads were generally less than one copy per thousand cells. The exceptions were four HPyV7-positive benign samples with viral loads ranging from 1 copy per 100 cells to one copy per seven cells and eight MCPyV-positive samples (two cSCC with viral loads of 2--5 copies per 100 cells and six benign lesions with viral loads from 1 copy per 100 cells to 1 copy per 4 cells).

### Co-detection of HPV and HPyV

At least one HPV type and one HPyV type were co-detected in 22/30 (73%) of lesions. There was no significant correlation between specific HPV and HPyV types. However, it was noteworthy that lesions from patient 6, which were all negative for HPV, were also largely negative for HPyV, despite having significant histological features of viral infection. Similarly, the cSCC for patient 4 was negative for all beta-PV and HPyV types tested.

Virus Status and Chromosomal Changes
------------------------------------

In order to examine gross chromosomal aberrations in vemurafenib-associated sSCC, we analyzed six well-differentiated cSCC from patient 1 using SNP array analysis to determine the signal values in tumor and paired non-tumor DNA at 250,000 SNPs throughout the genome. A comparison of tumor: non-tumor signal value ratios from vemurafenib-associated cSCC plotted according to chromosomal position with those from sporadic well-differentiated SCC analyzed in a previous study ([@B63]) revealed that the patterns of gross chromosomal aberrations were significantly different: none of these 6 cSCC had gross chromosomal aberrations and there were significantly fewer chromosomal changes compared with sporadic well differentiated SCC (**Figure [5](#F5){ref-type="fig"}**). There were no clear correlations with virus status identified.

![SNP microarray analysis of vemurafenib-associated cSCC. BRAFi-SCC did not display the gross chromosomal aberrations typically observed in sporadic cSCC ([@B63]). A running average of 2 consecutive tumor: non-tumor signal value ratios is plotted on a log2 scale according to chromosomal position. Upper line represents log2(2) and lower represents log2(0.5). **(A)** Copy number profiles of 5 vemurafenib-associated cSCC **(B)** Comparison with copy number profile from a sporadic cSCC showing 3p and 9p loss: these changes were characteristic of well-differentiated cSCC ([@B63]). Although chromosome 18 loss is also seen in this particular tumor, chromosome 18 aberrations were not as common as 3p and 9p changes in other sporadic well-differentiated cSCC ([@B63]). **(C)** More extensive allelic imbalance in a sporadic moderately-differentiated cSCC ([@B63]).](fmicb-09-01806-g005){#F5}

Virus Status and Association With Specific Genetic Mutations
------------------------------------------------------------

We have reported gene mutations identified by targeted sequencing in these 45 samples for *H, K* and *NRAS, NOTCH1 and 2, TP53, CDKN2A, CARD11, CREBBP, TGFBR1/2* and this has previously been presented in detail ([@B74]; [@B14]). In the current study we analyzed the association between these mutations and the presence of HPV and HPyV. HRAS mutations were identified in 5/12 (42%) SCC and 5/19 (31%) VW. Mutation did not correlate with sun-exposed sites or lesion type and no mutations were detected in normal skin samples (**Table [1](#T1){ref-type="table"}**). There was no significant difference between HRAS mutated vs. HRAS wild type lesions and HPV or HPyV status. The same was true for virus status and mutations in each of the other genes examined. Although it was noteworthy that v35 -- the most highly mutated SCC -- was negative for all viruses tested, there was no evidence of a significant correlation between overall mutational burden and virus status.

Virus Status and Clinical Response to Vemurafenib
-------------------------------------------------

There was no clear evidence of a significant association between virus status of lesions tested and prognosis in terms of disease progression and death from melanoma (data not shown).

Discussion
==========

We report HPV and HPyV analysis of 45 benign and malignant BRAFi-induced skin lesions from 7 individuals, including BRAFi-SCC and correlate this with clinical, histologic and genetic features. A high proportion of BRAFi-cSCCs had histologic viral wart-like features on histology, consistent with virus-driven processes, and the majority were positive for beta-PV, HPyV7 and MCPyV, which were co-detected in 73% of lesions tested. HPyV6 was found in one third of cases, but HPyV9 and TSPyV were rarely detected. As expected from previous studies of normal skin and hair follicles ([@B44]; [@B10], [@B9]; [@B62]), normal skin samples also harbored beta-PV, but the HPV burden of individual types detected was significantly fewer than in lesional skin. Histologic evidence of virus infection appeared to correlate with HPV burden. However, viral loads were low in the majority of lesions and validation by immunohistochemistry for HPV was negative in all but one of 12 cases. Gross chromosomal changes characterized by SNP arrays in BRAFi-cSCC indicated that these tumors have significantly fewer chromosomal aberrations than non-BRAFi-cSCC, providing a further indication that additional cofactors may be involved. However, we were unable to establish clear correlations between the presence of either HPV or HPyV and specific genetic mutations or total mutational burden.

Human Papillomaviruses and BRAFi-cSCC
-------------------------------------

Human papillomaviruses has been investigated as a potential viral carcinogen in BRAFi-cSCC since these drugs were first approved in 2011/2012: the rapid onset of skin lesions, their clinical morphology and viral wart-like histology all point to a possible role for HPV ([@B8]). Initial studies designed to detect alpha-PV infection by immunohistochemistry reported negative results ([@B2]; [@B18]; [@B52]). A surrogate for alpha-PV infection in mucosal sites is p16 immunoreactivity and in two studies the majority of BRAFi-cSCC were found to strongly express p16 ([@B2]; [@B8]), but this is not a consistent finding ([@B36]). Both approaches are less sensitive than PCR-based detection methodologies that have been used in other studies, although the latter are often limited by the use of formalin-fixed paraffin-embedded tissue (FFPE) and/or PCR primers detecting a limited range of HPV types. Using an alpha-PV specific PCR/line probe assay method, Dika et al failed to detect alpha-PV in 9 FFPE VK samples ([@B24]). Using the same assay together with a degenerate PCR methodology (FAP59/64) capable of detecting cutaneous HPV types, HPV was not detected in 8 BRAFi-cSCC/KA FFPE samples ([@B36]). Holderfield et al used the FPA 59/64 primers and additional degenerate primers (CP65/CP70 and CP66/CP69) and found 2/13 (15%) FFPE BRAFi-cSCC ([@B49]). [@B69] used E1 primers originally tested for alpha-PV types but theoretically capable of detecting any HPV type; in FFPE samples from 14 cSCC, 3 KA and one acanthoma, all were HPV positive, although the specific types detected were not reported. Subsequently, [@B20] used the most comprehensive degenerate PCR-based methodology in 69 FFPE BRAFi-cSCC and found all samples to be positive with predominantly beta-PV types of which HPV-17, HPV-38 and HPV-111 were the most common. [@B29] found 6/12 (50%) FFPE BRAFi-cSCCs to be positive, almost exclusively with beta-PV types including 12, 17, 24, 47, 124 and novel types but, as in our study, HPV positivity was not significantly different when compared to normal skin. However, we found a significant difference in HPV burden between lesional and normal skin in terms of the numbers of HPV types detected and it is possible that the total burden of HPV types as well as the specific types detected is relevant to potential pathogenic processes.

Against the background of these previous studies, our HPV detection methodology has notable strengths, although the data are still limited by small sample size. We have used a more comprehensive and sensitive approach to detecting HPV from alpha, beta, mu, nu, gamma genera with RHA and degenerate PCR/sequencing. We have also used fresh frozen tissue samples in order to reduce the likelihood of false negative results, which may occur with use of FFPE-derived DNA. Laser capture micro dissection allowed enrichment for lesional tissue and reduces the possibility of contamination by virus carriage in non-lesional tissue. Neither strategy for optimizing viral detection has been used in these previous studies. In addition, we used immunohistochemistry to try and understand the nature and significance of multiple HPV detection using a double staining technique not used in previous studies of BRAFi lesions.

Our study was not designed to address the functional significance of HPV detection in BRAFi-associated squamoproliferative skin lesions. To date, this has been attempted in only a few other studies. [@B37] used next-generation sequencing to look for viral transcripts indicative of active HPV infection: none were identified in 4 BRAFi-associated VK. Although this small study arguably calls into question a role for HPV, it is important to note that BRAFi-cSCC were not examined and the presence of very low abundance transcripts cannot be entirely excluded. In a compelling experimental approach, exposure to vemurafenib in a transgenic murine model (K14-HPV16 mice) of alpha-PV-driven cSCC was associated with an upregulation of the MAPK pathway and an increase in cSCC incidence from 22 to 70%. More than half of these tumors were *RAS* wild type, suggesting that vemurafenib and HPV may be cooperating to promote tumorigenesis in both the presence and absence of RAS mutations ([@B49]). Data from a more recent beta-PV transgenic mouse model provides evidence of significant synergism between beta-PV, UV, and BRAFi ([@B83]). The K14-HPV38 E6/E7 transgenic mouse expresses the beta-PV HPV38 E6 andE7 oncogenes in the basal layer of the epidermis under the control of the cytokeratin K14 promoter and requires UV exposure for AK and cSCC development ([@B85]). Vemurafenib increased the number and size of UV-induced cSCC. All BRAFi-treated transgenic mice developed cSCC by 34 weeks in contrast to none of the wild-type mice and only one-third of untreated transgenic mice. Ras mutations were not detected, but MAPK upregulation was evident in HPV38 E6/E7 over-expressing keratinocytes ([@B83]).

The mechanisms responsible for the synergism between HPV and BRAFi are speculative. However, experimental data indicate that upregulation of the MAPK pathway enhances alpha-PV replication, stability, and infectivity ([@B88]; [@B11]). If this is also the case for other HPV types, then it is possible that BRAFi-induced paradoxical upregulation of MAPK in the keratinocytes of normal skin -- which is likely to harbor beta-PV HPV ([@B44]; [@B10], [@B9]; [@B62]) -- also leads to enhanced replication and stability of these beta-PV. The resulting increased beta-PV viral load in normal keratinocytes may drive not only benign squamoproliferative lesions associated with BRAFi, but may also enhance synergism between the oncogenic effects of beta-PV and UV, independent of RAS status, which ultimately leads to increased carcinogenesis in the K14-HPV38-E6/7 transgenic murine model ([@B83]). Consistent with this, experimental evidence increasingly points to a "hit and run" role for beta-PV in skin ([@B78]). In contrast to high-risk alpha-PV which are required for both initiation and maintenance of a malignant phenotype in mucosal carcinogenesis, the hit-and-run hypothesis proposes that beta-PVs are required only at an early stage of carcinogenesis, with beta-PV E6 and E7 oncogenes facilitating accumulation of UV-induced DNA mutations in the host genome by means of multiple mechanisms that, for example, target DNA repair and apoptosis leading to inactivation of cellular tumor suppressor proteins or activation of oncoproteins ([@B21]; [@B50]; [@B64]; [@B78]; [@B84]). This is the "hit," which ultimately leads to cellular transformation ([@B84]). Viral oncogene expression is subsequently not required for maintenance of a malignant phenotype, rendering the viral genome dispensible and without consequence if lost from an established cancer -- the "run." This would explain the observations that beta-PV DNA loads are always significantly less than one viral genome copy per cell in cSCC and are generally higher in precancerous AK ([@B92]), that viral transciptomes are absent from BRAFi and non-BRAFi-cSCC ([@B4]; [@B37]), and are supported by together with findings in the recent murine K14-HPV38E6/7 transgenic models ([@B86]). However, although biologically plausible, this hypothesis remains to be definitively confirmed in human studies.

Such a hit-and-run role for beta-PV may also potentiate the deleterious effects of cSCC cofactors such as immune suppression and contribute to the higher susceptibility to cSCC of immune suppressed individuals such as solid organ transplant recipients ([@B45]). We and others have previously shown that beta-PV carriage is significantly more common in the normal skin and hair follicles of immune suppressed individuals ([@B91]) and, particularly in the presence of concordant beta-PV seropositivity, is associated with cSCC risk in both OTR ([@B62]; [@B9]) and immunocompetent individuals ([@B10]; [@B16]). Although detailed comparison of virus status in BRAFi- and non-BRAFi-associated cSCC might provide insight into the effects of BRAFi on the biological activity of beta-PV in skin, the small numbers of published studies in BRAFi-cSCC and the wide variations in HPV analyses used in these studies limit the power of such an analysis.

Human Polyomaviruses and BRAFi-cSCC
-----------------------------------

We detected HPyV6 in one third of all 30 lesions tested, HPyV7 in 60% and MCPyV in 73%, with no significant differences seen between benign and malignant lesions. In most cases the loads for all viruses were low. In our series HPyV9 was negative in all cases and TSPyV positive in just one cSCC. Our data for MCPyV are very similar to the 72% positivity reported in a series of 18 FFPE BRAFi-cSCCs ([@B69]) and 75% of 12 BRAFi-cSCC ([@B29]). In contrast, Cohen et al detected MCPyV in only 22% of 58 FFPE benign and malignant FFPE lesions ([@B20]) and a fourth study found MCPyV in only two of 19 VKs and none of 7 cSCCs ([@B36]). Of the few studies to examine other HPyVs, [@B69] found HPyV6 and 7 in all FFPE samples (14 cSCC, 3 KA, and one acanthoma), generally at low levels, although HPyV6 was present at high level and detectable by IHC in one cSCC. In contrast, in FFPE samples of 19 VKs, 1KA and 7 cSCC, [@B36] found no HPyV6 positivity and HPyV7 in one VK only. Once again, in all previous studies samples were FFPE rather than frozen samples and this, together with the tumor enrichment and PCR approaches used in our study, may account for some of these differences in HPyV detection.

We did not test normal skin samples, but MCPyV, HPyV6 and 7 are well-established members of the normal skin virome, with HPyV9 and TSPyV significantly less common ([@B68]; [@B35]; [@B51]; [@B94]). MCPyV has previously been detected in 40--62% of skin swabs from normal individuals ([@B93]; [@B68]) and HPyV6 and 7 have been detected in 14 and 11%, respectively ([@B68]). In comparison, HPyV9 and TSPyV were found in skin swabs from only 1/111 (0.9%) and 6/249 (2%) healthy individuals, respectively ([@B67]; [@B51]). A previous study analyzed MCPyV in 9 FFPE normal skin biopsies from patients with BRAFi-associated proliferative skin lesions and found all to be negative, whereas 5/9 (56%) were positive for HPV of predominantly beta-PV types ([@B29]). A case report by the same authors also failed to detect MCPyV in a normal skin of a patient with BRAFi-cSCC ([@B28]). Other HPyV have not been analyzed in normal skin from BRAFi-exposed individuals. These data provide a possible signal that HPyV6 and 7 are overrepresented in BRAFi-cSCC, with our findings of 36 and 54% positivity, respectively. However, as normal skin is frequently positive for MCPyV, our findings in BRAFi-cSCC are less convincing. However, this interpretation is speculative and needs to be confirmed in future studies that specifically include matched normal skin samples from BRAFi-exposed individuals.

To date, there have been no functional studies specifically addressing the role of HPyVs in BRAFi-cSCC. The oncogenic potential of MCPyV is well established in MCC ([@B19]; [@B60]) and it is plausible that the large and small T-antigen oncoproteins may be relevant in BRAFi-cSCC. To date, none of the 12 other HPyVs have been implicated in causing cancer ([@B19]). However, recent *in vitro* studies have indicated that MCPyV, HPyV6, and TSPyV can all induce cellular MAPK pathways ([@B98], [@B96],[@B97]). It is therefore, plausible that such activity may act synergistically with BRAFi-induced MAPK upregulation and contribute to driving squamoproliferative lesions.

Co-detection of HPV and HPyV
----------------------------

Human papillomavirus and HPyV were co-detected in the majority of virus positive lesions, usually at low copy number. There were no clear associations of specific types, although beta-PVs and MCPyV were most commonly co-detected, as previously reported ([@B28], [@B29]; [@B20]). Our interpretation of these data is limited by the fact we have only examined normal skin for HPVs and not for HPyVs. However, co-detection of these potentially oncogenic viruses in BRAFi-cSCC remains an important observation. Although it is not possible from these data to conclude whether one virus type is biologically more relevant than another in either driving the virus features seen histologically, the potential for their interaction in playing an oncogenic role merits further functional investigation. In particular, it is plausible that the ability of HPyV to upregulate MAPK and the effects of MAPK upregulation on HPV replication, infectivity and stability may act synergistically in enhancing the oncogenic potential of both in contributing to the pathogenesis of BRAFi-associated squamoproliferative lesions.

Virus Status and Genetic Alterations
------------------------------------

We have previously used SNP array analysis to show that UV-associated well-differentiated cSCC have significantly different patterns of chromosomal aberrations compared with moderately and poorly differentiated cSCC ([@B63]). Although BRAFi-cSCCs are histologically similar to well- differentiated sporadic cSCC, we have shown that they do not display the characteristic gross chromosomal aberrations typically associated with well-differentiated cSCC. This possibly reflects the shorter time course and more prominent role for MAPK upregulation induced by BRAFi, rather than through lifetime accumulated UVR-induced DNA damage, as seen in sporadic UV-associated cSCC ([@B53]). Arguably, however, it also provides circumstantial evidence for alternative etiological agents such as oncogenic viruses.

At the individual gene level, as previously reported, we found a significantly higher level of HRAS mutations in BRAFi-cSCC compared with non-BRAFi-cSCC ([@B74]). In the current study, we specifically sought a possible association with virus status in HRAS mutated compared with HRAS wild type lesions. This may provide insights into the mechanisms underlying carcinogenesis in BRAFi-cSCC that are additional to mutant HRAS-associated upregulation of the MAPK pathway and, for example, related to viral oncogenes. However, no clear correlation emerged between virus and HRAS status. We also specifically looked for evidence of an inverse association between the detection of virus and mutational burden in terms of the numbers of mutated genes, as is seen in MCC ([@B42]; [@B95]; [@B39]; [@B5]; [@B75]; [@B15]). Once again, no clear association emerged, although this study may have been underpowered to detect such an association.

Conclusion
==========

Despite the suggestive clinical and histologic evidence, a compelling experimental murine model and genetic evidence that HRAS mutations are absent in a significant proportion of BRAFi-induced squamoproliferative skin lesions, the contribution of HPVs and HPyVs to the development of these lesions suggested by results from previous studies remains inconclusive. The data presented here provide further circumstantial evidence for a possible role for HPV and HPyV. They also point to possible synergistic interactions between these potentially oncogenic skin viruses. Given the major increase predicted in adjuvant use of these agents in the near future, further research into the role of these and possibly other existing or novel members of the human skin virome is justified and may provide insights into the pathogenesis of other BRAF-induced skin disorders and malignancies.
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